Skip to main content
Xlife Sciences AG logo

Xlife Sciences AG — Investor Relations & Filings

Ticker · XLS ISIN · CH0461929603 LEI · 984500AH590BE88BB517 SW Professional, scientific and technical activities
Open in API
Filings indexed 287 across all filing types
Latest filing 2026-03-03 Declaration of Voting R…
Country CH Switzerland
Listing SW XLS

About Xlife Sciences AG

https://www.xlifesciences.ch/en/home

Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.

Recent filings

Filing Released Lang Actions
VERAXA Biotech Receives 99.57% Approval for Merger - Path to NASDAQ Listing Under VRXA Cleared
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release announcing the results of an Extraordinary General Meeting (EGM) where shareholders voted to approve a merger. While it mentions the merger, the primary purpose of the text is to report the outcome of the shareholder vote (99.57% approval). According to the filing definitions, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the correct category for official results from shareholder votes at any general meeting.
2026-03-03 English
VERAXA Biotech Receives 99.57% Approval for Merger - Path to NASDAQ Listing Under «VRXA» Cleared
M&A Activity Classification · 1% confidence The document is a press release announcing the results of an Extraordinary General Meeting (EGM) where shareholders approved a merger between VERAXA Biotech AG and Voyager Acquisition Corp. While it discusses a merger, the primary focus is the announcement of the shareholder vote results and the subsequent path to a NASDAQ listing. According to the filing definitions, announcements regarding merger proposals or takeover bids are classified as TAR (M&A Activity).
2026-03-03 English
VERAXA Biotech erhält 99,57% Zustimmung zur Fusion - Weg an die NASDAQ unter «VRXA» geebnet
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release announcing the results of an extraordinary general meeting (aoGV) regarding a merger between VERAXA Biotech AG and Voyager Acquisition Corp. While it mentions voting results, it is primarily an announcement of a corporate merger/acquisition (M&A) event. According to the filing definitions, documents detailing merger proposals or takeover bids are classified as TAR. Although it mentions voting results, it is not a formal declaration of voting rights (DVA) but rather a corporate news release about the merger progress.
2026-03-03 German
Update on Ongoing Transactions with Pharmaceutical Company Grupo Landsteiner and the NASDAQ Listing of VERAXA Biotech AG
Regulatory Filings Classification · 1% confidence The document is a corporate press release from Xlife Sciences AG providing an update on ongoing M&A-related transactions (partnership with Grupo Landsteiner and NASDAQ listing plans for VERAXA Biotech AG). It discusses strategic business developments rather than financial results, dividends, or regulatory filings. As it details specific merger and acquisition activities and corporate restructuring, it falls under the M&A Activity (TAR) category.
2025-12-31 English
Update on Ongoing Transactions with Pharmaceutical Company Grupo Landsteiner and the NASDAQ Listing of VERAXA Biotech AG
Regulatory Filings Classification · 1% confidence The document is a media release from Xlife Sciences AG providing an update on ongoing M&A transactions (Grupo Landsteiner) and corporate developments (VERAXA Biotech AG). It is a corporate announcement regarding business activities rather than a formal financial report, proxy statement, or audit. Given the focus on M&A and strategic partnerships, it fits the M&A Activity (TAR) category, as it details specific transaction progress and structural changes.
2025-12-31 English
Update zu den laufenden Transaktionen mit dem Pharmaunternehmen Grupo Landsteiner und dem NASDAQ-Listing der VERAXA Biotech AG
Regulatory Filings Classification · 1% confidence The document is a corporate press release from Xlife Sciences AG providing an update on ongoing transactions, specifically a partnership with Grupo Landsteiner and a NASDAQ listing plan for VERAXA Biotech AG. While it mentions a future general meeting, it is not a formal proxy or voting result document. It is a strategic update regarding M&A and corporate development activities. Since it does not fit into a specific financial report category like 10-K or IR, and is a general regulatory/corporate announcement, it is best classified as a Regulatory Filing (RNS).
2025-12-31 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.